Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...

StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...

Novo Nordisk A/S, Apollo Global Management, and Blackstone are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies that are ...